Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1774Neoplasms 1501Carcinoma, Non-Small-Cell Lung 1043Prostatic Neoplasms 957Colorectal Neoplasms 878Lung Neoplasms 800Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Leukemia, Myeloid, Acute 541Stomach Neoplasms 512Ovarian Neoplasms 507Neoplasm Metastasis 496Multiple Myeloma 495Recurrence 413Melanoma 386Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 355Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 305Endometrial Neoplasms 304Triple Negative Breast Neoplasms 299Glioblastoma 298Rectal Neoplasms 280Urinary Bladder Neoplasms 264Sarcoma 264Hematologic Neoplasms 264Colonic Neoplasms 254

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × BRCA1 Mutation × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

NCT05420064 2025-11-12

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Memorial Sloan Kettering Cancer Center

Phase NA Recruiting
1,000 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡